Streetbeat News

Stock Prices

AAL

AMSC

DWAC

LVTX

VERA

Benzinga's Stock Whisper Index highlighted five stocks: AAL, DWAC, VERA, AMSC, and LVTX. AAL reported strong Q4 results, beating estimates and receiving analyst upgrades, with shares up 13% in five days. DWAC shares hit two-year highs after Trump's primary wins and DeSantis' endorsement, with a SPAC merger deadline extended to March 8, 2024. VERA shares soared after positive Phase 2b trial results, leading to analyst upgrades and a 95% weekly gain. AMSC reported a 60% YOY revenue increase in Q3 and strong demand for new energy power systems. LVTX shares rose 40% after announcing a clinical trial collaboration with MRK for a prostate cancer treatment.

Portfolio Pulse from Chris Katje

January 26, 2024 | 4:50 pm

FCNCA

First Citizens BancShares Inc (NASDAQ:FCNCA) reported Q4 FY23 results with revenue of $1.91 billion, missing consensus estimates of $2.38 billion. Net interest income increased to $1.91 billion from $802 million a year ago, with improved margins. The CET 1 ratio improved to 13.36% from 10.08% a year ago. Adjusted EPS of $46.58 missed the consensus of $47.98. The provision for credit losses was $249 million, up from $79 million a year ago. Loans and leases totaled $133.30 billion, and deposits were $145.85 billion. A quarterly dividend of $1.64 per share was declared, payable on March 15, 2024. Despite missing revenue and EPS estimates, FCNCA shares surged 4.83% to $1,480.57.

Portfolio Pulse from Lekha Gupta

January 26, 2024 | 4:49 pm

INTC

Rosenblatt analyst Hans Mosesmann has reiterated a Sell rating on Intel Corporation (NASDAQ:INTC) and maintained a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 4:42 pm

AAL

DAL

JBLU

LUV

SAVE

UAL

Spirit Airlines (NYSE:SAVE) stock dropped 18% on Friday after JetBlue Airways (NASDAQ:JBLU) reported it could not meet all conditions of their $3.8 billion merger deal by the deadline. The deal, which faces antitrust challenges, may be terminated after January 28, 2024. Spirit's shares have fallen over 60% since the antitrust ruling. JetBlue would owe Spirit $70 million or $400 million to shareholders if the merger fails. Spirit anticipates Q4 2023 revenue at the high end of guidance, expecting $1.32 billion against a $1.31 billion consensus. As of December 31, 2023, Spirit had $1.3 billion in liquidity.

Portfolio Pulse from Anusuya Lahiri

January 26, 2024 | 4:41 pm

BAH

Booz Allen Hamilton Holding Corp (NYSE:BAH) reported strong third-quarter fiscal 2024 results, with a 12.9% year-on-year sales growth to $2.57 billion, surpassing the consensus of $2.54 billion. Adjusted EPS increased to $1.41 from $1.07, beating the consensus of $1.14. Operating margin improved significantly, and the company raised its quarterly dividend by $0.04 to $0.51 per share. Booz Allen also raised its FY24 outlook for sales growth, adjusted EPS, adjusted EBITDA, and operating cash flow. BAH shares surged 13.1% to $145.76 following the positive report.

Portfolio Pulse from Akanksha Bakshi

January 26, 2024 | 4:28 pm

DWAC

Shares of Digital World Acquisition Corp. (DWAC) are experiencing increased volatility due to recent successes of Donald Trump in GOP primaries and the ongoing civil defamation trial involving Trump. Trump-related stocks, including DWAC, are reacting to these political and legal events.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 4:28 pm

AMD

NVDA

TSM

Nvidia (NVDA) and AMD (AMD) stocks are trading lower after Bill Baruch of Blue Creek Capital and Joshua Brown of Ritholtz Wealth Management reduced their exposure to these semiconductor stocks. Brown, who maintains a core position in Nvidia, sold AMD shares, considering it overbought. Stephen Weiss of Short Hills Capital Partners favors Taiwan Semiconductor (TSM) over Nvidia and AMD, citing TSM's pricing power. Nvidia's stock has risen due to its AI chip industry position, with a $1 trillion opportunity in AI. AMD shares traded slightly lower at $179.94.

Portfolio Pulse from Anusuya Lahiri

January 26, 2024 | 4:26 pm

PCSA

Processa Pharmaceuticals Inc (NASDAQ:PCSA) saw its shares surge 148.8% to close at $5.10 on Thursday. The company announced a public offering of 1.56 million shares and warrants at $4.50, aiming to raise $7.0 million. Following the offering, the stock traded lower on high volume. Processa also completed a Phase 1b trial for NGC-Cap, selecting two dosage regimens for a Phase 2 trial in advanced breast cancer. On Monday, the stock began trading on a reverse split basis of 1-for-20, and on Friday, shares dropped 23.9% to $3.88 in premarket trading.

Portfolio Pulse from Vandana Singh

January 26, 2024 | 4:16 pm

MKC

JP Morgan analyst Ken Goldman has maintained an Underweight rating on McCormick & Co (NYSE:MKC) and reduced the price target from $59 to $57.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 4:14 pm

LPG

DNB Markets analyst Mats Bye has downgraded Dorian LPG (NYSE:LPG) from Buy to Hold and set a price target of $44.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 4:13 pm